Open AccessCisplatin Plus Gemcitabine as Standard of Care for Germline BRCA/PALB2‐Mutated Pancreatic Adenocarcinoma: Are We Moving Too Fast?
Author(s) -
Nicola Fazio
Publication year - 2020
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.20.00419
Subject(s) - veliparib , gemcitabine , medicine , palb2 , olaparib , parp inhibitor , brca mutation , oncology , cisplatin , pancreatic cancer , standard of care , germline , breast cancer , chemotherapy , germline mutation , cancer , cancer research , mutation , poly adp ribose polymerase , genetics , gene , biology , polymerase
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom